New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - ombitasvir 12.5mg; paritaprevir 75mg; ritonavir 50mg; dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg;  ; ribavirin 400mg;  ; ribavirin 600mg - film coated tablet - active: ombitasvir 12.5mg paritaprevir 75mg ritonavir 50mg excipient: colloidal silicon dioxide copovidone opadry pink 85f140088 propylene glycol monolaurate sodium stearyl fumarate sorbitan laurate tocofersolan active: dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg   excipient: colloidal silicon dioxide copovidone croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry beige 85f97497 active: ribavirin 400mg   excipient: carnauba wax croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry blue 85f90553 povidone active: ribavirin 600mg excipient: carnauba wax croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry blue 85f90623 povidone - indicated for the treatment of genotype 1 chronic hepatitis c infection, including patients with compensated cirrhosis, hiv-1 coinfection, and liver transplant recipients. duration of therapy and addition of ribavirin are dependent on patient population.

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - ombitasvir 12.5mg; paritaprevir 75mg; ritonavir 50mg; dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg;  ; ribavirin 400mg;   - film coated tablet - active: ombitasvir 12.5mg paritaprevir 75mg ritonavir 50mg excipient: colloidal silicon dioxide copovidone opadry pink 85f140088 propylene glycol monolaurate sodium stearyl fumarate sorbitan laurate tocofersolan active: dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg   excipient: colloidal silicon dioxide copovidone croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry beige 85f97497 active: ribavirin 400mg   excipient: carnauba wax croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry blue 85f90553 povidone - indicated for the treatment of genotype 1 chronic hepatitis c infection, including patients with compensated cirrhosis, hiv-1 coinfection, and liver transplant recipients. duration of therapy and addition of ribavirin are dependent on patient population.

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - ombitasvir 12.5mg; paritaprevir 75mg; ritonavir 50mg; dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg;  ; ribavirin 600mg;   - film coated tablet - active: ombitasvir 12.5mg paritaprevir 75mg ritonavir 50mg excipient: colloidal silicon dioxide copovidone opadry pink 85f140088 propylene glycol monolaurate sodium stearyl fumarate sorbitan laurate tocofersolan active: dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg   excipient: colloidal silicon dioxide copovidone croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry beige 85f97497 active: ribavirin 600mg   excipient: carnauba wax croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry blue 85f90623 povidone - indicated for the treatment of genotype 1 chronic hepatitis c infection, including patients with compensated cirrhosis, hiv-1 coinfection, and liver transplant recipients. duration of therapy and addition of ribavirin are dependent on patient population.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - 37685 - bag, medical device, reusable - the abbvie carrying accessories are designed to carry a cadd-legacy? 1400 pump. the abbvie carrying accessories are intended for single patient use only.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - 11677 - enteral feeding kit - the abbvie j is intended to provide long-term enteral access for administration of medication to the small intestine. the abbvie j is indicated for the administration of the medication duodopa (levodopa/carbidopa) intestinal gel.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - 35419 - tube, feeding, gastrostomy - the abbvie peg is intended to provide long-term enteral access for administration of medication to the small intestine when used in conjunction with the abbvie j intestinal tube. as needed, enteral nutrition may be administered directly to the stomach in parallel with medication delivery to the intestine. the abbvie peg is indicated for the administration of the medication duodopa (levodopa/carbidopa) intestinal gel.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - 16798 - tube, feeding, nasoenteral - the abbvie nj is intended to provide short-term enteral access for the administration of medicine to the small intestine. the abbvie nj is indicated for the administration of the medication duodopa (levodopa/carbidopa intestinal gel).

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - venetoclax 10mg;  ; venetoclax 50mg; venetoclax 100mg - film coated tablet - active: venetoclax 10mg   excipient: calcium hydrogen phosphate colloidal silicon dioxide copovidone opadry ii yellow 85f32450 polysorbate 80 purified water sodium stearyl fumarate active: venetoclax 50mg excipient: calcium hydrogen phosphate colloidal silicon dioxide copovidone opadry ii beige 85f97497 polysorbate 80 purified water sodium stearyl fumarate active: venetoclax 100mg excipient: calcium hydrogen phosphate colloidal silicon dioxide copovidone opadry ii yellow 85f32450 polysorbate 80 purified water sodium stearyl fumarate - venclexta is indicated for the treatment of patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - venetoclax 10mg;   - film coated tablet - 10 mg - active: venetoclax 10mg   excipient: calcium hydrogen phosphate colloidal silicon dioxide copovidone opadry ii yellow 85f32450 polysorbate 80 purified water sodium stearyl fumarate - venclexta is indicated for the treatment of patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - venetoclax 100mg;   - film coated tablet - 100 mg - active: venetoclax 100mg   excipient: calcium hydrogen phosphate colloidal silicon dioxide copovidone opadry ii yellow 85f32450 polysorbate 80 purified water sodium stearyl fumarate - venclexta is indicated for the treatment of patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).